CA2127877A1 - Improved process for preparing micronized polypeptide drugs - Google Patents
Improved process for preparing micronized polypeptide drugsInfo
- Publication number
- CA2127877A1 CA2127877A1 CA002127877A CA2127877A CA2127877A1 CA 2127877 A1 CA2127877 A1 CA 2127877A1 CA 002127877 A CA002127877 A CA 002127877A CA 2127877 A CA2127877 A CA 2127877A CA 2127877 A1 CA2127877 A1 CA 2127877A1
- Authority
- CA
- Canada
- Prior art keywords
- drug
- milling
- polypeptide
- nitrogen
- solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/193—Colony stimulating factors [CSF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/215—IFN-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/27—Growth hormone [GH] (Somatotropin)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
Abstract
Solid particle aerosol formulations of polypeptide drugs are made by lyophilizing solutions of the drugs which contain milling stabilizers that inhibit degradation of the drug during subsequent milling. The lyophilized drug is milled in fluid energy mills that have been fitted with abrasion-resistant materials and which use pure nitrogen that has been filtered to eliminate particles of greater than 0.1 µm to transport the drug. The use of (a) milling stabilizers in the solution and (b) abrasion-resistant fluid energy mills that use pure filtered nitrogen in the milling step reduce insoluble contaminants and inactive fractions in the milled product.
Description
W~9~ 7~ " ~ ,~ PCr/U~93/()037 IMPROVED PROCESS FOR PREPARING
MICRONIZE~ ~OLYPEPTIDE DRUGS
';, ' Descri~tion Technical Field The present invention is in the field of pharmaceutical formulation. More particularly, it concerns impxovements in a process for mi~!ronizing polypeptide drugs into powders that are suitable for ~:
formulation as solid particle aerosols.
..
Back~round Inhalation therapy involves the administration of a drug in ,an ~erosol form to:the respiratory tract.
2Q Two types of aerosols are employed: liquid:~particles an~
solid particles. The li~uid aerosols are generated by nebulizing solutions of the drug. Solid~particle ~--aerosols are either in the ~orm of a powder suspended in a propellant which is administered from a~metered dose .~;;
25 inhalèr or simply as a~powder that~is administered:~rom a -~
dry powder inhaler.: In the~case~of;~pol ~ eptide drugs, --`
solid particle aerosols~are~typ~ically~made~by; ~
:lyophilizing the~drug~f~om~solution and~:then:milling or ~ ~ .
grInding the lyophi:li:zed drug~to~the des;ired~parti~le size distribution~or~pulmOnarY~administration.~
Pri~r work~rs~haYe~r~eco~:ni:2~ed~certain sta~ility problems:in making such drugs~ First:, prior~;workers~have recognized th~t~remova~l of residual:~water during the~
ly~philization~:in;~the::presence~o~protective~agents pro~ides:a~more:stable~lyophili~ed~product.:~:~A~ ari~ty of :
~1~7~77 excipient3 hAv~ ~een propo~ed ~ ~u~ cryopro~ec~an~s (Pik~ .J-, aiQ~hg~ (1990) ~ (8) :18 ~7 and Frar~c3, F., 5~ (199D) ;L~ ~3-l~O.
Pr~or work~r~ ~a~r~ al~o r~cognizQ~ an~
5 add:ra~fied prob~s a~ocl;~ta3~ ~rith t~ 0tab-~ lity~ of ~rug powd~r~ t:hat a~r~ u~ud ~n ~lid pa~ttcl~ aero~ol~.
~h~e "~tabili~y~ pr~bl4~ rol~ p~xtlGl~ ng Dd~orbed ox ~or~3d ~y mate~lal~ in ~dhi~h ~y come lnto aonta~t durir~ r ~llng or t~0 part~cl~ f~r~ing 10 ag~;Lo~atos. For i~s~tanc~ ppll~a~lon ~ll~tic:n No. W~90/0~1 su~g~t~ u~lng ~a~nder" 2~0~ o ~oid p~rt~ d~orptie~n,, ~or~ion, or agylo~rat~on whil~ ter~ng th~ p2s:~iclo~ into unit do~ ~on~ r~.
~ong the ~ugg~t~d oxt~ .r~ ~no ~cid fs 15 (~lc:ular~iy Dl,~ onln~ on~, d~ nd poly~ac~:h~ri~o~ d polypapti~
~Surop~a~n Pa~nt ~pl~ iorl P~li~a~lon ~o.
03a~7~ d~ C~ 55 il!l p:rOC~llG ~r re~u¢~ng th0 particl~
~Ya o~ proteir~ ma~er~.~l u~ id ~rgy ~ra ~B no m~ntic~n ~ m~d~lc~tioA o~ th~ or ~
a~d~ il?islg ~tabiliæ~r~ to aY~a dlas~ t~n of the pro~s~n ~3at~ria~ o t~ o~ applicant~' Xnowl~dg~, t~8 art ha~ nc)t ~c:ogni~d or adelra~ d~ r7ou~
Q~o~t~ 0~ e gr~~ C?r ~nilllng 3Qtop of th~ p4w~1er 25 produc:~on on ~he ~olubillty a~ biologic~l aatl~rity o~
~a p2~u6t pow~ In t~ g~d, t~ ese~t lon ~ ~lr~c~ 4r ~ g th~ o~t~
n~olubla ~ l and ~c1O5~1G~lly ~nactiYe m~t~r~1 p~ c~ wh~ a p~alyp~p~ds d~g ~æ lycph~llze~ and 30 mi~l~d lr~to ~!a pow~ r a~ tr~io~ a~ a ~ol~
pa~iol~ ~ro~
.
Th~ i~ventl~ ~:~lat~ o 13~pro~ en~ in a 35pro~ or pr~pa~:L~g a ~i~roni~ polyp~p~lde ~rug in ~JI~TliT~ ~ET
.. .. . . .... . ..
. .
~ 1~ 7~77 wh~:~h a ~lution o~ ru~ is lyoph~ liz~d a~d the lyop~lizad drug la~ Qd to ~ pow~er in a f luid ~ner~y s~lll u~iny a p-~8~uri28d ~3d ~I!IIB. On~ ~p~o~reman~
co~prises usln3 2~ puri~i8d ~n~r~ ~ ga~ wh~oh Aa~ b~en filterad to re~o~e p~lc1~3~ ~aat~ n about o.l ,~
fro~ the ~'a~d gA~ who~ ate~ in~olubls cQnt~nanta in th~ pow~EIr are re~uce~. ~notl~ prov~mant ~pplie~ to in~tanc~ w~or~ ~ drug i8 1A~1S und~ ~ m~ll~g ~o~it~on~ ~ compr~ in~orpoxatirlS~ a ~sl~iing ~tablli~ tb~, p~ pt~d~ d~ wb,~e~y ~he produ~on o~ b~o~t~g~o~l7y lna~vQ ~t~r~ n ~hc ~ llng s~ep :IES
r~uo~d.
~ Lgh~ n~an . ~ia prh~ant ~n~ u~0~ul ~or tran~ror~in~ polypepti~ drug~ ~nto ~ pow~ o~ th2~t iB
3ui~able ~o~ o~ol admiAi~xalt~on or ~r use ln in~ec~bl~ ~u~p~ lon~s~ a~ u~lad h~r~in, ~ t~
l~polyp~pti~s~ in~ d~ ~o~ u~s c~o~d Or a~out 10 or
MICRONIZE~ ~OLYPEPTIDE DRUGS
';, ' Descri~tion Technical Field The present invention is in the field of pharmaceutical formulation. More particularly, it concerns impxovements in a process for mi~!ronizing polypeptide drugs into powders that are suitable for ~:
formulation as solid particle aerosols.
..
Back~round Inhalation therapy involves the administration of a drug in ,an ~erosol form to:the respiratory tract.
2Q Two types of aerosols are employed: liquid:~particles an~
solid particles. The li~uid aerosols are generated by nebulizing solutions of the drug. Solid~particle ~--aerosols are either in the ~orm of a powder suspended in a propellant which is administered from a~metered dose .~;;
25 inhalèr or simply as a~powder that~is administered:~rom a -~
dry powder inhaler.: In the~case~of;~pol ~ eptide drugs, --`
solid particle aerosols~are~typ~ically~made~by; ~
:lyophilizing the~drug~f~om~solution and~:then:milling or ~ ~ .
grInding the lyophi:li:zed drug~to~the des;ired~parti~le size distribution~or~pulmOnarY~administration.~
Pri~r work~rs~haYe~r~eco~:ni:2~ed~certain sta~ility problems:in making such drugs~ First:, prior~;workers~have recognized th~t~remova~l of residual:~water during the~
ly~philization~:in;~the::presence~o~protective~agents pro~ides:a~more:stable~lyophili~ed~product.:~:~A~ ari~ty of :
~1~7~77 excipient3 hAv~ ~een propo~ed ~ ~u~ cryopro~ec~an~s (Pik~ .J-, aiQ~hg~ (1990) ~ (8) :18 ~7 and Frar~c3, F., 5~ (199D) ;L~ ~3-l~O.
Pr~or work~r~ ~a~r~ al~o r~cognizQ~ an~
5 add:ra~fied prob~s a~ocl;~ta3~ ~rith t~ 0tab-~ lity~ of ~rug powd~r~ t:hat a~r~ u~ud ~n ~lid pa~ttcl~ aero~ol~.
~h~e "~tabili~y~ pr~bl4~ rol~ p~xtlGl~ ng Dd~orbed ox ~or~3d ~y mate~lal~ in ~dhi~h ~y come lnto aonta~t durir~ r ~llng or t~0 part~cl~ f~r~ing 10 ag~;Lo~atos. For i~s~tanc~ ppll~a~lon ~ll~tic:n No. W~90/0~1 su~g~t~ u~lng ~a~nder" 2~0~ o ~oid p~rt~ d~orptie~n,, ~or~ion, or agylo~rat~on whil~ ter~ng th~ p2s:~iclo~ into unit do~ ~on~ r~.
~ong the ~ugg~t~d oxt~ .r~ ~no ~cid fs 15 (~lc:ular~iy Dl,~ onln~ on~, d~ nd poly~ac~:h~ri~o~ d polypapti~
~Surop~a~n Pa~nt ~pl~ iorl P~li~a~lon ~o.
03a~7~ d~ C~ 55 il!l p:rOC~llG ~r re~u¢~ng th0 particl~
~Ya o~ proteir~ ma~er~.~l u~ id ~rgy ~ra ~B no m~ntic~n ~ m~d~lc~tioA o~ th~ or ~
a~d~ il?islg ~tabiliæ~r~ to aY~a dlas~ t~n of the pro~s~n ~3at~ria~ o t~ o~ applicant~' Xnowl~dg~, t~8 art ha~ nc)t ~c:ogni~d or adelra~ d~ r7ou~
Q~o~t~ 0~ e gr~~ C?r ~nilllng 3Qtop of th~ p4w~1er 25 produc:~on on ~he ~olubillty a~ biologic~l aatl~rity o~
~a p2~u6t pow~ In t~ g~d, t~ ese~t lon ~ ~lr~c~ 4r ~ g th~ o~t~
n~olubla ~ l and ~c1O5~1G~lly ~nactiYe m~t~r~1 p~ c~ wh~ a p~alyp~p~ds d~g ~æ lycph~llze~ and 30 mi~l~d lr~to ~!a pow~ r a~ tr~io~ a~ a ~ol~
pa~iol~ ~ro~
.
Th~ i~ventl~ ~:~lat~ o 13~pro~ en~ in a 35pro~ or pr~pa~:L~g a ~i~roni~ polyp~p~lde ~rug in ~JI~TliT~ ~ET
.. .. . . .... . ..
. .
~ 1~ 7~77 wh~:~h a ~lution o~ ru~ is lyoph~ liz~d a~d the lyop~lizad drug la~ Qd to ~ pow~er in a f luid ~ner~y s~lll u~iny a p-~8~uri28d ~3d ~I!IIB. On~ ~p~o~reman~
co~prises usln3 2~ puri~i8d ~n~r~ ~ ga~ wh~oh Aa~ b~en filterad to re~o~e p~lc1~3~ ~aat~ n about o.l ,~
fro~ the ~'a~d gA~ who~ ate~ in~olubls cQnt~nanta in th~ pow~EIr are re~uce~. ~notl~ prov~mant ~pplie~ to in~tanc~ w~or~ ~ drug i8 1A~1S und~ ~ m~ll~g ~o~it~on~ ~ compr~ in~orpoxatirlS~ a ~sl~iing ~tablli~ tb~, p~ pt~d~ d~ wb,~e~y ~he produ~on o~ b~o~t~g~o~l7y lna~vQ ~t~r~ n ~hc ~ llng s~ep :IES
r~uo~d.
~ Lgh~ n~an . ~ia prh~ant ~n~ u~0~ul ~or tran~ror~in~ polypepti~ drug~ ~nto ~ pow~ o~ th2~t iB
3ui~able ~o~ o~ol admiAi~xalt~on or ~r use ln in~ec~bl~ ~u~p~ lon~s~ a~ u~lad h~r~in, ~ t~
l~polyp~pti~s~ in~ d~ ~o~ u~s c~o~d Or a~out 10 or
2 0 ~.~e a~no ~c:id~ lin~ p~ nd3 . T~ ~
~olyp~ld~ ~ay inc:lude mssl~ e~, e.$l~,0 sugir~ othgr lno ~C~,dB, or b~ co~ d wl~:h otb~x ~o~e~
~u~h ~ liplas. E~ample~ o~ ~uc:~: polyE;~p~id~ ar~
~nsullsl, ~nt~r~ero~ t~r~er~n ,8, ints~ron~y, ~n~rls~in 1 7, g~a~nulo6yta colo~y a~ mula~lnç~ ~actor ac~oph~g~ ~ran~lloc~ c~ ti3lul~ acto7 ~C~F~, ~pl~m;a,l gro~ tor (BaF) ~ ln~uli~ Q
~o~th ~a~or~ 1 ~nd 2 ~ Sor~in~ ~ro~ :.`
~actor ~ ~T~ 3, tr~n~f~ ~owt~ ~ac:tQr~ 3
~olyp~ld~ ~ay inc:lude mssl~ e~, e.$l~,0 sugir~ othgr lno ~C~,dB, or b~ co~ d wl~:h otb~x ~o~e~
~u~h ~ liplas. E~ample~ o~ ~uc:~: polyE;~p~id~ ar~
~nsullsl, ~nt~r~ero~ t~r~er~n ,8, ints~ron~y, ~n~rls~in 1 7, g~a~nulo6yta colo~y a~ mula~lnç~ ~actor ac~oph~g~ ~ran~lloc~ c~ ti3lul~ acto7 ~C~F~, ~pl~m;a,l gro~ tor (BaF) ~ ln~uli~ Q
~o~th ~a~or~ 1 ~nd 2 ~ Sor~in~ ~ro~ :.`
~actor ~ ~T~ 3, tr~n~f~ ~owt~ ~ac:tQr~ 3
3~ t~F-,Bl, 2 ar3d 3), ~s~u~ pl~og~: ~tlvator CTPA~
~late~o~-d~ri~ ro~h ~ or ( PDG~, e~poi1at~n ($P0) ~ an gro~th ho~r~ an8 o~er ~ormos~
gro~h ~actor~ and n~ pt~ id~
a~ ba pxepared by i~ol~ng ~a ~m ~ ources ~i (body tilll~U~i8 or ~lul~æ~, b~ e~t~e~ nq t~ by ~;
s~B~r~ $~
.. _ __,. _ . . . . _. . .. _ ... . . .~.
r~ ~ 7 7 ~elca~b3nant D~IA t~a~nolo~ in t:h2 C~8e v~ r~latlvaly ~11 molecul~s, ~y i3ynth~ g l~ y ~olid-pha~e ~echn~ques with or w~thou~ ligat~on.
lrhe ~ ~ r~t 3't6!!p in ~h~ proc~ or ~o~mlng the 5 po~ypept~d4e in~o laicron~zed ~art~ol~ lyophillz~t~o21.
I~ ~e polypep~id~ ~ lsola~d o~ ~ynthpBl~ad 1~ i~
30.1ution, no ~olven~ n~d b~ ad~ in ;~ ~y ~ta~ h~ ~o~ypaptld~ 1~ dl~olY~d ln an app~opr~ ata ~olv~nt. ~n D~any ~nst~ncas, th~ ptidc~ is water 10 ~olubl~. It w~ll be ~ppr6aciat~ t~t lo~ s~ gy pol~e~ 3 ~ ~ r~ire us~ o~ 8 Ç~Qat~ re3~ 0~
r4nt. qbe pol~ ptl~ lyo~l~z~ 3~0~1 a f~o~n so~utlon., ~ ha poly~ labil~ tlD ~ oonditlo~
to wh~Ch i~ sub~ct~ during mill~ng (i-~to~
15 l?r~ur~l t~pax~tur~ ill;Lr~g ~ Gr 1~ addQd o~ut~orl. ~u~ ~bll~ 3 includ~ ~u~
sorbitol~ ~a~lto~ uc:~oa~, la~at~ n~ t~
~ur~a~t~ntsz ~uc~ ~ poly~ ylp3~01$don~, and T~Jat~-~olu~ prot~s su~h a~ ~e~ ~ bovin~, ~an, chlck~s, go;D~, at~.~. Th~ ~ wlll n~ y ~
A~ ild to t~ ~;olu ion a~ aonc~ ons o~ 0.5 tc) ~ -mgls~l, pr~f~rably 1 to 2o ~n~J~l. 80r~tol i~ co~ln2~tlon wi~ othar ~uçlarE~ pr~r~ ~
Alt~ati~ely, th~ ~6ta~ilizor ~ay ~ x~d ho~og~n~ou$1~v 2~ with th~ lyop~ d c~ k will b~ ~ppa:~iat~d ~hat ~a ~pti~ ~ ~ or c03~a~n~ti~n ~ &~r~
r~} d~g to ~ug~ an~ opti~ tab~liz~Jar(~) a~ a3aoun~ o~ stabiliz~r ~4~ a g~an p~lyp~ptid~ y n~d ~o b~s ~e~ r1eally.
Th~ ~olu~ion i~ lyo~hil~d ~ re~z~aq ~h~
.~olut~on a~ su~c:tlng th~ g~oæem 3~ to ConY~ntional lyop~ li2~1tion ~ipm~nt ~y ~o u~d.
~w~ c~Dle~o -~oo~ 6 era~y ~ t~ -~5~ ~ B~d ~o a ~a~u~a o~
0. S x 104 ~o 7 . ~x ~0~ #r~ t p~s~ably 1. o aZ
.
.. .
S~ ET ~`
~.
, 7 ~
104 to 2 . 5 x 104 N~c>nE~ t~ (50 to 750 ~illlto~r, pre~eraDly ~o~ to as~ milli~o~r) fox~ 50 tO ~20 hou:rs, ~h~ lyoph~ d polypaptide i~ n ~z~ :
ra~uce~ in ~ ~rt nd~n~ , p~e~arably ~ ~ uid energy 5 mill ~l~o ~ m a~ ~ ~t mlll. The3~ o;mploy h~yh VQ~oc~ity ga~ ~tx~ o ~rry ~e~d pa:rticl~ o oont~ct wi~: ~ach o~e:r ;an~./or th~ ~ur~ o~ ~ grindlng cham~ser. ~n on~ t~ h~ ~lu~d sna:rgy i~ adinitto~ ~ria .
multiplia$ty o~ hig~ v~14c~ty ~2~8 ~ ~$ at ~n ~sngle 10 a~ ~d a pnrt~lon Csr ~ll o~ ~ehe per~ph~y cs~ a ~l~n~i~al milling-da~3i~y~n~ ~B~ a~oth~ t~e, ~luid ~trea~ ~::C?rlvoy ~3 ps~rt~al~s h~ h~4 V~IlD~lty lrlte~ a :ih~ ~~ two f3tX~ i~pa~t upon ~acb. o~ n i!~not~l;aX ~yp~ 0 ~lUi~ trQ~m o~n~ pllrt~ClBEs 5 ~a~n~ct ~a ~tatio~aa.ry i~pact ~ a or around a torol~l nnel~ I~ a~ll /'C~B t*~ a high ~n~rgy relea~e a~d hlgh or~ler o~ c:~ Whi~ au00~ t~8 p~ al~ to ~rt~d upon ~h~lV~s ~d upon tha m~ e ~nd to b~ -~ractura~. Mo~t mil~ cla~ y pa~o~es ~en~r~f~ 11y 20 U~ing ~:h~ ~n~ lu~ ~t~ a~d ~Ye ~an~ ~r r~turrl~ng o~ p2~c:le~ t;!4 tb~3l gr~nd~ng ch~b6r ~or ~urtker ~ se r~ductlon~ ~pl~ Je~fi are p~e~r~d. ~x~mple~s o~ ~o~ro~ odlma~ o~
Buoh ~ xe ~ ~icr~niz~r ~6'cu~ nt ~ Corp,)~ :
th4 ~ vBX~z~r ~t ~ul~ o-), u~:tioni~er, ~ a~O~On~ er~ ro~t ~I.N~, an~
@ ~ O~ ~a~ly ~ oD~r~ a cyl~n~cal gri~ing ~a~sa~ ~her~ln ~ lyophlliz~
p~lypep~ e ~Ug ~a a~ed Upon by a nr~ o~ g~ ~o~ ~
3Q ~ ir,g ~ou~h ori*i~ ced ~rc~und ~ p~ ph~sy O~ :
- t~ a~ r. Th~ r~ tin~ d~ar~ Bt ~:h8 cej~t:er o~ hs~3~ c rry1ng ~ ~ne~ wlth it, whil~ the coa~ a~15~ w~ t~w~r~ ~ 6~ ~ll wh~
u~ r r~clu~:t~n ~ ~
35 p~rti~ a~sd g~sl ln ~ in~2lng ~t~ ~e outl~t rrOm , .,. ~
th~ grt nd.lng ch~b~r nozmal~y l~ad~ ~rsctly into a c~ntrl~ug;!ll p~oduct c(~lla¢tor~
~ n ord~ to r~dur~ e a3~oun~ o~ ln~oluble conta~inan~e ~ .J m~ar~ ~at ~re lr~solu~le in wa~er 5 at 3~) presont in t~ roduct p~wd~rJ ~pp2ic~nts h~
modl~ied t~o con~ t~onal ~l~Llln~ proc~e ~n ~eve:r~ ;
:~portant re~peat~ ~irE t, a~y p~t~3 o~ th~ ~ill (e.g., ~old~r o~ weld ~ nt~ that ~a~ e~ ~o abra~ton and d~ ation ar~ r~plaaod wit~a ~a~r~ls that are ~aore 10 r~.Ri~æ~nnt tu abra~ion ~ dagra~ on under the ~ill~ng ~nd~t~on. q~cond, ~ ln~t ~d ga~ nitro~n~ i~
u~o~ to ~ e th~ p~iel~. r~ r~3gar~ a t~r~
"inert" lnt~ t ~h- ga~ ~rill not r~a~st with t~e ~y~pbLilize~ ~e~ ~at~rial u~d~ g con~lt~on~.
d n~ r~s~r~xr~ sou~c~ o~ inert ga~ ~-bQcau~a i~ ~ u~trapu~ ~d it h~l~ cool ~e ~ d ~`
~8 p~u¢t. Th~ , th~ lncami.ng ~a~d gas ~s ~ilter~d . :~
prio~ to ~rod~uation ~n~o th~ o ~ t~
cc~n~ n~ 1Q~ U~ C1~
20 ~al~2~tion ~sy be ~c:co~pll~haa ~ 3~la~ing co~m~r::ially a~ail~ tultr~igh ~1Gie~¢Y) ~ r~ t~
W~erg~rd, ~i lllp~r~ inao~g g~ llne~
TJs~ o~ high purity ~a~ do~ bl~ avoid lntrodu~in~ cont~ to ~h3 polyp~pl:id~. -2~ A~ indi~t~ abo~, app~c~t~ y ::
ng ~t~1112Or~ ~o r~d~3 8haa:s:, ~e~e ~n~/o~
stur~ ~zld~t1O~l o$ th~a ~ao~ ptld~ dru~ Th~3e ~t~b~llz~ may ~lua pro~ct ~h@ ~ol~pt~d~ ~ro~
d~ dation durin~ ly~p~ zat~ ~d/~r du~in 3~ ~tor~
- !~o p~rti~ o~ the ~t~ powde~
prl~ri`ly ~p~nd~a~ u~on ~~ rgy i~ rt~ by t~
to ~ p~ M whi~ ir~ ~ ' r~l~ts~ eo th~ pre~alure o~ th~ ~od ~ præ~oux~ 1 n~r~aally: r~g~
3~ ~e~ bout ~.~ x 105 t~ 9O3 x 10~ N2wton~/m~t~r2, ~r~
',:
, ", ~1~7877 u~ually 6 l, 5 X lO~ ~o ~ . 6 x 105 NewtonsJ~ter2 ~ lo tc~ l~o p5ig, ~orQ u~uall,~ ~o to llO p~q). ~n g~eral, l~wer pres~3ur~s in th~A ra~g~ ~i.e., 1.7 x 105 to 3.1 x 105 Nawt:ona~ ter2 ~tO to 3~ p6iç~) W~ll produce largsr 5 partiolea ( L . ~ ., 4 tD 3.5 ~ i~l d~ t~r) wh~r~a~ h~
prea~ura~ l produc~ 3~aaller pa~tic~ ., 0.5 to
~late~o~-d~ri~ ro~h ~ or ( PDG~, e~poi1at~n ($P0) ~ an gro~th ho~r~ an8 o~er ~ormos~
gro~h ~actor~ and n~ pt~ id~
a~ ba pxepared by i~ol~ng ~a ~m ~ ources ~i (body tilll~U~i8 or ~lul~æ~, b~ e~t~e~ nq t~ by ~;
s~B~r~ $~
.. _ __,. _ . . . . _. . .. _ ... . . .~.
r~ ~ 7 7 ~elca~b3nant D~IA t~a~nolo~ in t:h2 C~8e v~ r~latlvaly ~11 molecul~s, ~y i3ynth~ g l~ y ~olid-pha~e ~echn~ques with or w~thou~ ligat~on.
lrhe ~ ~ r~t 3't6!!p in ~h~ proc~ or ~o~mlng the 5 po~ypept~d4e in~o laicron~zed ~art~ol~ lyophillz~t~o21.
I~ ~e polypep~id~ ~ lsola~d o~ ~ynthpBl~ad 1~ i~
30.1ution, no ~olven~ n~d b~ ad~ in ;~ ~y ~ta~ h~ ~o~ypaptld~ 1~ dl~olY~d ln an app~opr~ ata ~olv~nt. ~n D~any ~nst~ncas, th~ ptidc~ is water 10 ~olubl~. It w~ll be ~ppr6aciat~ t~t lo~ s~ gy pol~e~ 3 ~ ~ r~ire us~ o~ 8 Ç~Qat~ re3~ 0~
r4nt. qbe pol~ ptl~ lyo~l~z~ 3~0~1 a f~o~n so~utlon., ~ ha poly~ labil~ tlD ~ oonditlo~
to wh~Ch i~ sub~ct~ during mill~ng (i-~to~
15 l?r~ur~l t~pax~tur~ ill;Lr~g ~ Gr 1~ addQd o~ut~orl. ~u~ ~bll~ 3 includ~ ~u~
sorbitol~ ~a~lto~ uc:~oa~, la~at~ n~ t~
~ur~a~t~ntsz ~uc~ ~ poly~ ylp3~01$don~, and T~Jat~-~olu~ prot~s su~h a~ ~e~ ~ bovin~, ~an, chlck~s, go;D~, at~.~. Th~ ~ wlll n~ y ~
A~ ild to t~ ~;olu ion a~ aonc~ ons o~ 0.5 tc) ~ -mgls~l, pr~f~rably 1 to 2o ~n~J~l. 80r~tol i~ co~ln2~tlon wi~ othar ~uçlarE~ pr~r~ ~
Alt~ati~ely, th~ ~6ta~ilizor ~ay ~ x~d ho~og~n~ou$1~v 2~ with th~ lyop~ d c~ k will b~ ~ppa:~iat~d ~hat ~a ~pti~ ~ ~ or c03~a~n~ti~n ~ &~r~
r~} d~g to ~ug~ an~ opti~ tab~liz~Jar(~) a~ a3aoun~ o~ stabiliz~r ~4~ a g~an p~lyp~ptid~ y n~d ~o b~s ~e~ r1eally.
Th~ ~olu~ion i~ lyo~hil~d ~ re~z~aq ~h~
.~olut~on a~ su~c:tlng th~ g~oæem 3~ to ConY~ntional lyop~ li2~1tion ~ipm~nt ~y ~o u~d.
~w~ c~Dle~o -~oo~ 6 era~y ~ t~ -~5~ ~ B~d ~o a ~a~u~a o~
0. S x 104 ~o 7 . ~x ~0~ #r~ t p~s~ably 1. o aZ
.
.. .
S~ ET ~`
~.
, 7 ~
104 to 2 . 5 x 104 N~c>nE~ t~ (50 to 750 ~illlto~r, pre~eraDly ~o~ to as~ milli~o~r) fox~ 50 tO ~20 hou:rs, ~h~ lyoph~ d polypaptide i~ n ~z~ :
ra~uce~ in ~ ~rt nd~n~ , p~e~arably ~ ~ uid energy 5 mill ~l~o ~ m a~ ~ ~t mlll. The3~ o;mploy h~yh VQ~oc~ity ga~ ~tx~ o ~rry ~e~d pa:rticl~ o oont~ct wi~: ~ach o~e:r ;an~./or th~ ~ur~ o~ ~ grindlng cham~ser. ~n on~ t~ h~ ~lu~d sna:rgy i~ adinitto~ ~ria .
multiplia$ty o~ hig~ v~14c~ty ~2~8 ~ ~$ at ~n ~sngle 10 a~ ~d a pnrt~lon Csr ~ll o~ ~ehe per~ph~y cs~ a ~l~n~i~al milling-da~3i~y~n~ ~B~ a~oth~ t~e, ~luid ~trea~ ~::C?rlvoy ~3 ps~rt~al~s h~ h~4 V~IlD~lty lrlte~ a :ih~ ~~ two f3tX~ i~pa~t upon ~acb. o~ n i!~not~l;aX ~yp~ 0 ~lUi~ trQ~m o~n~ pllrt~ClBEs 5 ~a~n~ct ~a ~tatio~aa.ry i~pact ~ a or around a torol~l nnel~ I~ a~ll /'C~B t*~ a high ~n~rgy relea~e a~d hlgh or~ler o~ c:~ Whi~ au00~ t~8 p~ al~ to ~rt~d upon ~h~lV~s ~d upon tha m~ e ~nd to b~ -~ractura~. Mo~t mil~ cla~ y pa~o~es ~en~r~f~ 11y 20 U~ing ~:h~ ~n~ lu~ ~t~ a~d ~Ye ~an~ ~r r~turrl~ng o~ p2~c:le~ t;!4 tb~3l gr~nd~ng ch~b6r ~or ~urtker ~ se r~ductlon~ ~pl~ Je~fi are p~e~r~d. ~x~mple~s o~ ~o~ro~ odlma~ o~
Buoh ~ xe ~ ~icr~niz~r ~6'cu~ nt ~ Corp,)~ :
th4 ~ vBX~z~r ~t ~ul~ o-), u~:tioni~er, ~ a~O~On~ er~ ro~t ~I.N~, an~
@ ~ O~ ~a~ly ~ oD~r~ a cyl~n~cal gri~ing ~a~sa~ ~her~ln ~ lyophlliz~
p~lypep~ e ~Ug ~a a~ed Upon by a nr~ o~ g~ ~o~ ~
3Q ~ ir,g ~ou~h ori*i~ ced ~rc~und ~ p~ ph~sy O~ :
- t~ a~ r. Th~ r~ tin~ d~ar~ Bt ~:h8 cej~t:er o~ hs~3~ c rry1ng ~ ~ne~ wlth it, whil~ the coa~ a~15~ w~ t~w~r~ ~ 6~ ~ll wh~
u~ r r~clu~:t~n ~ ~
35 p~rti~ a~sd g~sl ln ~ in~2lng ~t~ ~e outl~t rrOm , .,. ~
th~ grt nd.lng ch~b~r nozmal~y l~ad~ ~rsctly into a c~ntrl~ug;!ll p~oduct c(~lla¢tor~
~ n ord~ to r~dur~ e a3~oun~ o~ ln~oluble conta~inan~e ~ .J m~ar~ ~at ~re lr~solu~le in wa~er 5 at 3~) presont in t~ roduct p~wd~rJ ~pp2ic~nts h~
modl~ied t~o con~ t~onal ~l~Llln~ proc~e ~n ~eve:r~ ;
:~portant re~peat~ ~irE t, a~y p~t~3 o~ th~ ~ill (e.g., ~old~r o~ weld ~ nt~ that ~a~ e~ ~o abra~ton and d~ ation ar~ r~plaaod wit~a ~a~r~ls that are ~aore 10 r~.Ri~æ~nnt tu abra~ion ~ dagra~ on under the ~ill~ng ~nd~t~on. q~cond, ~ ln~t ~d ga~ nitro~n~ i~
u~o~ to ~ e th~ p~iel~. r~ r~3gar~ a t~r~
"inert" lnt~ t ~h- ga~ ~rill not r~a~st with t~e ~y~pbLilize~ ~e~ ~at~rial u~d~ g con~lt~on~.
d n~ r~s~r~xr~ sou~c~ o~ inert ga~ ~-bQcau~a i~ ~ u~trapu~ ~d it h~l~ cool ~e ~ d ~`
~8 p~u¢t. Th~ , th~ lncami.ng ~a~d gas ~s ~ilter~d . :~
prio~ to ~rod~uation ~n~o th~ o ~ t~
cc~n~ n~ 1Q~ U~ C1~
20 ~al~2~tion ~sy be ~c:co~pll~haa ~ 3~la~ing co~m~r::ially a~ail~ tultr~igh ~1Gie~¢Y) ~ r~ t~
W~erg~rd, ~i lllp~r~ inao~g g~ llne~
TJs~ o~ high purity ~a~ do~ bl~ avoid lntrodu~in~ cont~ to ~h3 polyp~pl:id~. -2~ A~ indi~t~ abo~, app~c~t~ y ::
ng ~t~1112Or~ ~o r~d~3 8haa:s:, ~e~e ~n~/o~
stur~ ~zld~t1O~l o$ th~a ~ao~ ptld~ dru~ Th~3e ~t~b~llz~ may ~lua pro~ct ~h@ ~ol~pt~d~ ~ro~
d~ dation durin~ ly~p~ zat~ ~d/~r du~in 3~ ~tor~
- !~o p~rti~ o~ the ~t~ powde~
prl~ri`ly ~p~nd~a~ u~on ~~ rgy i~ rt~ by t~
to ~ p~ M whi~ ir~ ~ ' r~l~ts~ eo th~ pre~alure o~ th~ ~od ~ præ~oux~ 1 n~r~aally: r~g~
3~ ~e~ bout ~.~ x 105 t~ 9O3 x 10~ N2wton~/m~t~r2, ~r~
',:
, ", ~1~7877 u~ually 6 l, 5 X lO~ ~o ~ . 6 x 105 NewtonsJ~ter2 ~ lo tc~ l~o p5ig, ~orQ u~uall,~ ~o to llO p~q). ~n g~eral, l~wer pres~3ur~s in th~A ra~g~ ~i.e., 1.7 x 105 to 3.1 x 105 Nawt:ona~ ter2 ~tO to 3~ p6iç~) W~ll produce largsr 5 partiolea ( L . ~ ., 4 tD 3.5 ~ i~l d~ t~r) wh~r~a~ h~
prea~ura~ l produc~ 3~aaller pa~tic~ ., 0.5 to
4 ,u~ in ~ et~r).
Th~ ire~ partlc~ or ~ g1vE~n polypal?t~de drllg will d~p~Dnd upss~ th~ ~t6~ in the ~:
10 ~plratory t:r c~ :~o~ which ~ dnlg is ~ar~at~
Gena!~ally, par~c1~ ow ~bc~ut 4 ,u~ in dla~e~ter ~u~l~y o~.s to 4 l~m~ wlll dap~8~t i~ t~ie th~r~pau~ica~!ly e~Ot~ Q low~r pul~c~n~ gion3 whe~ ~dmini~ d a~a an a6~0sol into t~e ~plra,~ory tx~t w~A;~aa~ larger 15 par~ lo~ ~i to 10 ~Lm) wlll lodg~a ln th~a upp~r airway~ o~
th~ ro~pl~atory tra~t. Il~ will b~ ~ppr~ !Lt ~:h8 pHrtid~ e~ raal~d h~ n r~r~ to a ~ -di~trlbutisn o~ p~t~c113~ de~ 4d by t~ n di~meter ~wh~ara ~0~ o~ s~ o~ ~ partlcl~ bO'VQ ~`
20 She ~tat~ 2e a2~ O~c o~ a5el ~8 ~low th~ ~ta~
~iz~3. Partia7e ~ ~y b~ d~3tg~aine!~ ~y coD~ercially a~ailabl~ par1:1cl~ . slze ~alyz~
By u~ing the ~m~roY~d p~o~ o~ th~ ln~en~ion, ~-ln~oluble aont~ina~t:~ ~n t~e po~der pr~uct are r~duc~d 25 ~c? ~l~w ~u~ ~% ~7y w~lght, morE~ u~ually b~low a~out 231 ~y w~ig~t. ~h61~ conta~in~n~ b~ ~oun~ tc~
incraa~ d~ on og t~e a~iY~ d~L~nt lr~ the ~lle~ ~?oW~ produc~ In ~ o~ polypop~d~ th~t ~e ~the~i~ ~a~d by ~j~t ~lling~ the ~mre~tl6:n :' ~0 r~uc~a t~o ~ nt o~ de~ ior~uc~ tha~he palypeptid~ dru~ e~onspon~nt o~ d powd~x ~o~s~ s ~ #~ t ~ t~ ?r~ x~bl~ ~t ~a~t abou~ ~S~ zac:t~
T~ powd~ ~y ~ ~ul~ w~ a 35 pr~p~ll4nt ~o~ 4~D,inl-txati~r~ v;LIl :set~r~d dose ir~l~r :~ ~
''' ~ . .
ST~ g!~
~7~7 de~rices, ~he propellar~t w~ll normEI17y be ~ hydrocarbon or halo~ydrocar~30n ~uc~ tetr~luoroetha~ae, ~ichloro~l~Ao~om~th~n~, dic~lot~ luoro~&thane, ~nd 'che 1~ k~ . ~ur~a::~a~tc~ miily ~e adde~l to t~a ~ormula.tlon to
Th~ ire~ partlc~ or ~ g1vE~n polypal?t~de drllg will d~p~Dnd upss~ th~ ~t6~ in the ~:
10 ~plratory t:r c~ :~o~ which ~ dnlg is ~ar~at~
Gena!~ally, par~c1~ ow ~bc~ut 4 ,u~ in dla~e~ter ~u~l~y o~.s to 4 l~m~ wlll dap~8~t i~ t~ie th~r~pau~ica~!ly e~Ot~ Q low~r pul~c~n~ gion3 whe~ ~dmini~ d a~a an a6~0sol into t~e ~plra,~ory tx~t w~A;~aa~ larger 15 par~ lo~ ~i to 10 ~Lm) wlll lodg~a ln th~a upp~r airway~ o~
th~ ro~pl~atory tra~t. Il~ will b~ ~ppr~ !Lt ~:h8 pHrtid~ e~ raal~d h~ n r~r~ to a ~ -di~trlbutisn o~ p~t~c113~ de~ 4d by t~ n di~meter ~wh~ara ~0~ o~ s~ o~ ~ partlcl~ bO'VQ ~`
20 She ~tat~ 2e a2~ O~c o~ a5el ~8 ~low th~ ~ta~
~iz~3. Partia7e ~ ~y b~ d~3tg~aine!~ ~y coD~ercially a~ailabl~ par1:1cl~ . slze ~alyz~
By u~ing the ~m~roY~d p~o~ o~ th~ ln~en~ion, ~-ln~oluble aont~ina~t:~ ~n t~e po~der pr~uct are r~duc~d 25 ~c? ~l~w ~u~ ~% ~7y w~lght, morE~ u~ually b~low a~out 231 ~y w~ig~t. ~h61~ conta~in~n~ b~ ~oun~ tc~
incraa~ d~ on og t~e a~iY~ d~L~nt lr~ the ~lle~ ~?oW~ produc~ In ~ o~ polypop~d~ th~t ~e ~the~i~ ~a~d by ~j~t ~lling~ the ~mre~tl6:n :' ~0 r~uc~a t~o ~ nt o~ de~ ior~uc~ tha~he palypeptid~ dru~ e~onspon~nt o~ d powd~x ~o~s~ s ~ #~ t ~ t~ ?r~ x~bl~ ~t ~a~t abou~ ~S~ zac:t~
T~ powd~ ~y ~ ~ul~ w~ a 35 pr~p~ll4nt ~o~ 4~D,inl-txati~r~ v;LIl :set~r~d dose ir~l~r :~ ~
''' ~ . .
ST~ g!~
~7~7 de~rices, ~he propellar~t w~ll normEI17y be ~ hydrocarbon or halo~ydrocar~30n ~uc~ tetr~luoroetha~ae, ~ichloro~l~Ao~om~th~n~, dic~lot~ luoro~&thane, ~nd 'che 1~ k~ . ~ur~a::~a~tc~ miily ~e adde~l to t~a ~ormula.tlon to
5 facllitat~e and eta~aili2~ l:h~ ~u8p~nf~i~n ~nd d~ ~p~rsi~n o~
tl~e powd~r in the prGp~ nt an~ t~ lubr~ca~ inhaler ~om;?on~nt~., Th~ drug pow~er ~11 nor~ally conRtit~e ~bout 0.1 to 1~ by ~reig~t of t~ ormula~ n9 more u~ually ~.S t~ 2.~ by w~sh~:-~e D~ll~a p~dar a~Ry ~ ~o~nuls~ with ~ulking 21gent3 or~ Lni~t~re~ n~at ~r~ o~d~r $nh~1er davlc~ bulXlDg ag~an~ u~ea,.~oy w~
o~titute about ~0% to g~. 9g9 o~ ~
~ormulatiorl. :
~ e eoli~l partlul~ a~a:ro~sl o~ ~he polyp~ptid~
~ug wlll b~ a~Aini~ a in on~3 or ~or~ unit do8e~ t~
pro-~ride t~er~pQu~ vsl~ o~ e drug. ~he ~o~ Or polyp~ptide ~mini~te!r~ J~nd t~l2 d~ing ~gimerl will ~p~d upon ~h~ 7pa~ci~ r drug b~lng ac3m~nis~er~d, theo l~ic~tion baing ~e~ed7 ~nd t~Q ~atien~ Ac~ordlnq~y, e ~ppr~ia~ t~a~ p~ci~ic ~c~t and rag~n u~d i~ ~yen lllstan~ y vary widely.
~he ~ollowing ~ pl~$ ~ h~r lllu~tr~ta a5 ~n~entio~ T~ exa~p~ a~ not int~n~ed ts~ llmlt ~ention ~n ~y ~na~r.
~phil~z~d r~co~ibinan'c ~n growth ho~mone ' was obtain~d ~rom th~ ~nu~a~turea~ Or ~!ua@. ~ ;
~1~7~7~
~L~
A Stur~4vant H~cron~ tar ; 11 tmo~ ) w~
u3ed . origlnal ly th~ ~e~d g~ to ~ w~a ~ed in ~t ? . 3 x 1~5 Nc~ ng:J~ter~ ~ 0~ y~ . Th49 in6;~
s ~rac~ion ~n ~hg ~lled product ~ala cl~ts~in~d ~y U~Vr sp~ctr~ph~t~met~ . In ia~lt~al rullo app~oxim~ely 4 o~ ~y WeLi~ht oi~ the~ ro~u~ wa~ in~olubl~.
~rhe in~ol~l~ ~rz~ctton ~a r~duc~d ~o 209~
wQlght by (1~ r~ cing tho E~i1V~ ~old~d ~oirlt~ ~n thQ ~.
10 ~1 with w~l~sd ~o~nt~ ~nd (2~ x6~pl~cln~ th2 ~old~red cop~ a3 lin~with ~ iblo ~nlral~ ;t~el ho eL The in~ol~ r~a.c~lon wa~ f~hor r~ducs~ ~o 3 to 15~ ~y W0iSlh~ by (1) rapla¢ln~ Stur~srant g~ ol~ wit~
~ mani~ld mzl~ o~ eloc:tr~pollohe~ st~ le3i~c ~t~ol tubing 15 2~nd VC~,aollp~ing6~, ~2) in~ 3al~t~n pArtic:l~
~llter ~ EX te~t~d Por ~mov~sg 0.1 ~ p~tl~le~ a~
g9.99~ ~æ~6i~y3, ~n~ ~3~ g wit~ 9~.~9~
nltr~Te~ ex r~duc:tion o~ in~olubl~ ~at~r~al wao a~v~d by al~ring tho ~wd3x-~eed ~e~anisz~ to pr~v~ont~
20 ~t ~rom d:r~wing c:ont~ e:~ r~ y ~u~plyirag tho g~ ~r~ d ni~ogen d~ ~ con~ a~s. ~h~
in~lub^l3 ~raction ~a~ ~ur~er raduced to 2.5 to ~.5~ by w~ t by xeplac~n~ t~a g~ :man~ro~d wil~ ~ htgh p~ri~ ~:~
g~3 manifold ~nd ul~a hlgh purlty f ilt~ ~Wafer~d~
por~, ~nc. ) .
U~ ~lut~ a~n~ oll~3wi~g 3~ co~po~i'clon~ w~r~ p~a~
I~?N~,B 13 ,u~ 15 :.~g/~ ~5 l~bg/~
Hu~arl ~i0~ ~g,/~ 15 m~ 445 ~/2~ ~ ~
Al3~ in .:
S~3~3~F~ 9~EEr _ .__ _. . . . . _ _ .. _..... . .... . 1 . ~
--10~
NaCl CJ . 6 m~ O . 6 ~g/7~ o ~ 584 mg/~
S~rbitoi - 4 . 5 mg~ _ Th~ ~lut~ 3 ly~phlli2~ raeza d~Dr t~o~l~l No. GT4, ~, Col~ Y) ~ h~ ~et mlll d~xi~d ~n E;~C~P'1A 1 t:ka prov~d~d th~ l~t3t raduc~ o~ ~n~ol~Lblss~ w~s u~esl. The ril~er ~n 'che ~ a ga~ lln~ ~ Db~inQd ~ro~ ~ll~or~ -corp~ ocl~or~, ~).
~ ho mill WJt.B op~r~d ~ ~ O ~ 3c ~05 - 7 . ~ x 10~;
N~w~on~me!t~ 80-lO0 ~3~g) ac:co~ing to ~D.nu~aature~
~nast~c'cionE~ ~c pro~ a p~wd~ ~a~ng ç~ater ~an ~0~
;15 c~ ~he p~t~ cloe 1~ thaY~ 3 ~ 4n dia~ter an~l 9~% o~ :
p~ le~ tls~ S ,~ .n s2ia~a~t~
~ e lyo~l~ d pe~d~ e~ora mic3~nl~ation~
~r,a th~ roni2~d powdox~ we~l~ æ~s~d ~c~r Ii~
a~tivity u~g a~ an~y~e ~:no~s8~y (E~ Yam~
2û al.~ ~D I~am~oà~say ~.sa9~ ~;!S~ r~ults ~r~
~ollaw~
y ~3a~ore ~c:ti~ity A~ter 107~ 5 A a%
25~ 3 . 8~
10 . 4*~ D 5 ~ 8 r~ ~ * 1 " 3 %
:
~ ~0~r t~e ~O~LI~ iD~ at Oo~lt~in~d bo~ ~ nd~ ~o~b~tol ~ o~
~llling ~ U~ n~ o;~ ~&I~ y.
~ue~ou~ 3eo~ulAtion8l~ c~ GC~IP a~ ~ ~g/~, 35 g~y~ln~ ~C~ at ~ r~;, ~nd ~ tol, la~c;to~
~: 3~ ~T ~ ~ ~
~11 ~ucro3~ at lo my~ we:re :~ad~, lyophili~ed and ~~ d.
nitrogenr ~illl ng pre~ure 7 . g x 105 Ne~ na~ ter2 ~1~0 p~ ), wa~ us~d ~th a *e~ r~tQ o~ the l~?op~ d ~at~r~al o~ 0.5 gf~in. ~e milllng ~ppa~atu~ w~ th~t 5 u~d ln E~a~ple 2 alaotr~, T~ 118~ powd~r~ co~taln~d in~ignlPic~nt ~moun~8 Or i~olt~ rial but ~lgnlricant ~o~lntJs o~ ~olubl~ ag~ga~e3.
n an ~t~mpt to ~ t~ ~olt~ aggrega~
~ a~uo~U~ ~os~ul~on o~ ç;cs~ a~ 1-0 ~g~ a~anitol a~
10 s.o m~Jm~ ~d ~ ol a~ 1.0 ~; uas ~fids, 1YOP~ B~
2nd ~il3~d az~ ~bov~- ~he addlt~on 0:~ ~03~b~tol ~educe~
tbe i~l p~ soluble~ 0gat~0 in t~e ~ o~d~r to 7. 6~Ap~.os o~ u~ill~d powd~ an8 3~1111e~ p5w~
o~ B i~rmula~ion wer~ r~c:o~ itut~ ln glycin~;5 bu~aro~ r ~pP. 3.,5) an~ ly~d ~ ~ xolu~on HP
ato~phy. ~, re~ul~ sr ~a~ aph~ ~n~
t:hs~ wa~ ig~ ant ~eg~a~l~tion ~ tha po~rd~ by l~h~
mill ir~g ~
~o~i~icatlo~ o~ ~he ~3:oy~-d~c~l~u31 mod~ x c~ryin~ oat ~a~ in~ntion t~ O]~ OU8 t;:o ~hOB~ O
skill i2~ ~c f~ pharmac~ut~c~l ~or~ula~io~ ~nd rel tÆ~ d~ ntend~d ~o ~ wit~ scopa o~
~ollo~lng clai~.
.
~.
'~
tl~e powd~r in the prGp~ nt an~ t~ lubr~ca~ inhaler ~om;?on~nt~., Th~ drug pow~er ~11 nor~ally conRtit~e ~bout 0.1 to 1~ by ~reig~t of t~ ormula~ n9 more u~ually ~.S t~ 2.~ by w~sh~:-~e D~ll~a p~dar a~Ry ~ ~o~nuls~ with ~ulking 21gent3 or~ Lni~t~re~ n~at ~r~ o~d~r $nh~1er davlc~ bulXlDg ag~an~ u~ea,.~oy w~
o~titute about ~0% to g~. 9g9 o~ ~
~ormulatiorl. :
~ e eoli~l partlul~ a~a:ro~sl o~ ~he polyp~ptid~
~ug wlll b~ a~Aini~ a in on~3 or ~or~ unit do8e~ t~
pro-~ride t~er~pQu~ vsl~ o~ e drug. ~he ~o~ Or polyp~ptide ~mini~te!r~ J~nd t~l2 d~ing ~gimerl will ~p~d upon ~h~ 7pa~ci~ r drug b~lng ac3m~nis~er~d, theo l~ic~tion baing ~e~ed7 ~nd t~Q ~atien~ Ac~ordlnq~y, e ~ppr~ia~ t~a~ p~ci~ic ~c~t and rag~n u~d i~ ~yen lllstan~ y vary widely.
~he ~ollowing ~ pl~$ ~ h~r lllu~tr~ta a5 ~n~entio~ T~ exa~p~ a~ not int~n~ed ts~ llmlt ~ention ~n ~y ~na~r.
~phil~z~d r~co~ibinan'c ~n growth ho~mone ' was obtain~d ~rom th~ ~nu~a~turea~ Or ~!ua@. ~ ;
~1~7~7~
~L~
A Stur~4vant H~cron~ tar ; 11 tmo~ ) w~
u3ed . origlnal ly th~ ~e~d g~ to ~ w~a ~ed in ~t ? . 3 x 1~5 Nc~ ng:J~ter~ ~ 0~ y~ . Th49 in6;~
s ~rac~ion ~n ~hg ~lled product ~ala cl~ts~in~d ~y U~Vr sp~ctr~ph~t~met~ . In ia~lt~al rullo app~oxim~ely 4 o~ ~y WeLi~ht oi~ the~ ro~u~ wa~ in~olubl~.
~rhe in~ol~l~ ~rz~ctton ~a r~duc~d ~o 209~
wQlght by (1~ r~ cing tho E~i1V~ ~old~d ~oirlt~ ~n thQ ~.
10 ~1 with w~l~sd ~o~nt~ ~nd (2~ x6~pl~cln~ th2 ~old~red cop~ a3 lin~with ~ iblo ~nlral~ ;t~el ho eL The in~ol~ r~a.c~lon wa~ f~hor r~ducs~ ~o 3 to 15~ ~y W0iSlh~ by (1) rapla¢ln~ Stur~srant g~ ol~ wit~
~ mani~ld mzl~ o~ eloc:tr~pollohe~ st~ le3i~c ~t~ol tubing 15 2~nd VC~,aollp~ing6~, ~2) in~ 3al~t~n pArtic:l~
~llter ~ EX te~t~d Por ~mov~sg 0.1 ~ p~tl~le~ a~
g9.99~ ~æ~6i~y3, ~n~ ~3~ g wit~ 9~.~9~
nltr~Te~ ex r~duc:tion o~ in~olubl~ ~at~r~al wao a~v~d by al~ring tho ~wd3x-~eed ~e~anisz~ to pr~v~ont~
20 ~t ~rom d:r~wing c:ont~ e:~ r~ y ~u~plyirag tho g~ ~r~ d ni~ogen d~ ~ con~ a~s. ~h~
in~lub^l3 ~raction ~a~ ~ur~er raduced to 2.5 to ~.5~ by w~ t by xeplac~n~ t~a g~ :man~ro~d wil~ ~ htgh p~ri~ ~:~
g~3 manifold ~nd ul~a hlgh purlty f ilt~ ~Wafer~d~
por~, ~nc. ) .
U~ ~lut~ a~n~ oll~3wi~g 3~ co~po~i'clon~ w~r~ p~a~
I~?N~,B 13 ,u~ 15 :.~g/~ ~5 l~bg/~
Hu~arl ~i0~ ~g,/~ 15 m~ 445 ~/2~ ~ ~
Al3~ in .:
S~3~3~F~ 9~EEr _ .__ _. . . . . _ _ .. _..... . .... . 1 . ~
--10~
NaCl CJ . 6 m~ O . 6 ~g/7~ o ~ 584 mg/~
S~rbitoi - 4 . 5 mg~ _ Th~ ~lut~ 3 ly~phlli2~ raeza d~Dr t~o~l~l No. GT4, ~, Col~ Y) ~ h~ ~et mlll d~xi~d ~n E;~C~P'1A 1 t:ka prov~d~d th~ l~t3t raduc~ o~ ~n~ol~Lblss~ w~s u~esl. The ril~er ~n 'che ~ a ga~ lln~ ~ Db~inQd ~ro~ ~ll~or~ -corp~ ocl~or~, ~).
~ ho mill WJt.B op~r~d ~ ~ O ~ 3c ~05 - 7 . ~ x 10~;
N~w~on~me!t~ 80-lO0 ~3~g) ac:co~ing to ~D.nu~aature~
~nast~c'cionE~ ~c pro~ a p~wd~ ~a~ng ç~ater ~an ~0~
;15 c~ ~he p~t~ cloe 1~ thaY~ 3 ~ 4n dia~ter an~l 9~% o~ :
p~ le~ tls~ S ,~ .n s2ia~a~t~
~ e lyo~l~ d pe~d~ e~ora mic3~nl~ation~
~r,a th~ roni2~d powdox~ we~l~ æ~s~d ~c~r Ii~
a~tivity u~g a~ an~y~e ~:no~s8~y (E~ Yam~
2û al.~ ~D I~am~oà~say ~.sa9~ ~;!S~ r~ults ~r~
~ollaw~
y ~3a~ore ~c:ti~ity A~ter 107~ 5 A a%
25~ 3 . 8~
10 . 4*~ D 5 ~ 8 r~ ~ * 1 " 3 %
:
~ ~0~r t~e ~O~LI~ iD~ at Oo~lt~in~d bo~ ~ nd~ ~o~b~tol ~ o~
~llling ~ U~ n~ o;~ ~&I~ y.
~ue~ou~ 3eo~ulAtion8l~ c~ GC~IP a~ ~ ~g/~, 35 g~y~ln~ ~C~ at ~ r~;, ~nd ~ tol, la~c;to~
~: 3~ ~T ~ ~ ~
~11 ~ucro3~ at lo my~ we:re :~ad~, lyophili~ed and ~~ d.
nitrogenr ~illl ng pre~ure 7 . g x 105 Ne~ na~ ter2 ~1~0 p~ ), wa~ us~d ~th a *e~ r~tQ o~ the l~?op~ d ~at~r~al o~ 0.5 gf~in. ~e milllng ~ppa~atu~ w~ th~t 5 u~d ln E~a~ple 2 alaotr~, T~ 118~ powd~r~ co~taln~d in~ignlPic~nt ~moun~8 Or i~olt~ rial but ~lgnlricant ~o~lntJs o~ ~olubl~ ag~ga~e3.
n an ~t~mpt to ~ t~ ~olt~ aggrega~
~ a~uo~U~ ~os~ul~on o~ ç;cs~ a~ 1-0 ~g~ a~anitol a~
10 s.o m~Jm~ ~d ~ ol a~ 1.0 ~; uas ~fids, 1YOP~ B~
2nd ~il3~d az~ ~bov~- ~he addlt~on 0:~ ~03~b~tol ~educe~
tbe i~l p~ soluble~ 0gat~0 in t~e ~ o~d~r to 7. 6~Ap~.os o~ u~ill~d powd~ an8 3~1111e~ p5w~
o~ B i~rmula~ion wer~ r~c:o~ itut~ ln glycin~;5 bu~aro~ r ~pP. 3.,5) an~ ly~d ~ ~ xolu~on HP
ato~phy. ~, re~ul~ sr ~a~ aph~ ~n~
t:hs~ wa~ ig~ ant ~eg~a~l~tion ~ tha po~rd~ by l~h~
mill ir~g ~
~o~i~icatlo~ o~ ~he ~3:oy~-d~c~l~u31 mod~ x c~ryin~ oat ~a~ in~ntion t~ O]~ OU8 t;:o ~hOB~ O
skill i2~ ~c f~ pharmac~ut~c~l ~or~ula~io~ ~nd rel tÆ~ d~ ntend~d ~o ~ wit~ scopa o~
~ollo~lng clai~.
.
~.
'~
Claims
Claims 1. In a process for preparing a micronized polypeptide drug comprising lyophilizing a solution of the drug in a solvent and milling the lyophilized drug in a fluid energy mill using a pressurized gas, the improvement comprising using a pure inert gas filtered to remove particles greater than about 0.1 µm in diameter as the gas, whereby insoluble contaminants in the powder are reduced, and the improvement wherein the parts of the mill that are contacted by the presurized gas in which the polypeptide is being carried are not substantially abraded by the drug-carrying gas.
2. The process of claim 1 wherein the polypeptide drug is labile under the milling conditions and the lyophilized drug contains a milling stabilizer.
3. The process of claim 2 wherein the milling stabilizer comprises sorbitol, mannitol, sucrose, lactose, trehalose, serum albumin, polyvinylpyrrolidone, or mixtures thereof.
4. The process of claim 1 wherein the inert gas is nitrogen of greater than about 99% purity.
5. The process of claim 4 wherein the pressure of the nitrogen is in the rang e of 1.6 x 105 to 9.3 x 105 Newtons/meter2 (10 to 120 psig).
6. The process of claim 5 wherein the source of the nitrogen is liquid nitrogen.
7. The process of claim 1 wherein the particle size of the micronized polypeptide drug is in the range of about 0.5 to 15 µm.
8. The process of claim 1 wherein the solvent is water.
10. The process of claim 1 wherein the micronized polypeptide drug is suitable for administration as a solid particle aerosol.
11. In a process for preparing a micronized polypeptide drug comprising lyophilizing a solution of the drug in a solvent and milling the lyophilized drug in a fluid energy mill using a pressurized gas wherein the polypeptide drug is libile under the milling conditions, the improvement wherein a milling stabilizer is added to the polypeptide drug.
12. The process of claim 11 wherein the milling stabilizer comprises sorbitol, mannitol, sucrose, lactose, trehalose, serum albumin, polyvinylpyrrolidone, or mixtures thereof.
13. The process of claim 1 wherein the milling stabilizer is added to the solution.
14. The process of claim 13 wherein the concentration of milling stabilizer in the solution is 0.5 to 50 mg/ml.
2. The process of claim 1 wherein the polypeptide drug is labile under the milling conditions and the lyophilized drug contains a milling stabilizer.
3. The process of claim 2 wherein the milling stabilizer comprises sorbitol, mannitol, sucrose, lactose, trehalose, serum albumin, polyvinylpyrrolidone, or mixtures thereof.
4. The process of claim 1 wherein the inert gas is nitrogen of greater than about 99% purity.
5. The process of claim 4 wherein the pressure of the nitrogen is in the rang e of 1.6 x 105 to 9.3 x 105 Newtons/meter2 (10 to 120 psig).
6. The process of claim 5 wherein the source of the nitrogen is liquid nitrogen.
7. The process of claim 1 wherein the particle size of the micronized polypeptide drug is in the range of about 0.5 to 15 µm.
8. The process of claim 1 wherein the solvent is water.
10. The process of claim 1 wherein the micronized polypeptide drug is suitable for administration as a solid particle aerosol.
11. In a process for preparing a micronized polypeptide drug comprising lyophilizing a solution of the drug in a solvent and milling the lyophilized drug in a fluid energy mill using a pressurized gas wherein the polypeptide drug is libile under the milling conditions, the improvement wherein a milling stabilizer is added to the polypeptide drug.
12. The process of claim 11 wherein the milling stabilizer comprises sorbitol, mannitol, sucrose, lactose, trehalose, serum albumin, polyvinylpyrrolidone, or mixtures thereof.
13. The process of claim 1 wherein the milling stabilizer is added to the solution.
14. The process of claim 13 wherein the concentration of milling stabilizer in the solution is 0.5 to 50 mg/ml.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US82321892A | 1992-01-21 | 1992-01-21 | |
| US07/823,218 | 1992-01-21 | ||
| PCT/US1993/000373 WO1993013752A1 (en) | 1992-01-21 | 1993-01-20 | Improved process for preparing micronized polypeptide drugs |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2127877A1 true CA2127877A1 (en) | 1993-07-22 |
Family
ID=25238119
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002127877A Abandoned CA2127877A1 (en) | 1992-01-21 | 1993-01-20 | Improved process for preparing micronized polypeptide drugs |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US5354562A (en) |
| EP (1) | EP0621774B1 (en) |
| JP (1) | JPH07503154A (en) |
| AT (1) | ATE146359T1 (en) |
| CA (1) | CA2127877A1 (en) |
| DE (1) | DE69306755T2 (en) |
| WO (1) | WO1993013752A1 (en) |
Families Citing this family (113)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5993805A (en) * | 1991-04-10 | 1999-11-30 | Quadrant Healthcare (Uk) Limited | Spray-dried microparticles and their use as therapeutic vehicles |
| US5811447A (en) * | 1993-01-28 | 1998-09-22 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
| US6515009B1 (en) | 1991-09-27 | 2003-02-04 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
| US6582728B1 (en) | 1992-07-08 | 2003-06-24 | Inhale Therapeutic Systems, Inc. | Spray drying of macromolecules to produce inhaleable dry powders |
| US6509006B1 (en) | 1992-07-08 | 2003-01-21 | Inhale Therapeutic Systems, Inc. | Devices compositions and methods for the pulmonary delivery of aerosolized medicaments |
| US5770609A (en) * | 1993-01-28 | 1998-06-23 | Neorx Corporation | Prevention and treatment of cardiovascular pathologies |
| US6251920B1 (en) | 1993-05-13 | 2001-06-26 | Neorx Corporation | Prevention and treatment of cardiovascular pathologies |
| US6395494B1 (en) | 1993-05-13 | 2002-05-28 | Neorx Corporation | Method to determine TGF-β |
| US6306421B1 (en) | 1992-09-25 | 2001-10-23 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
| DE4242863A1 (en) * | 1992-12-18 | 1994-06-23 | Boehringer Mannheim Gmbh | Stable lyophilized pharmaceutical preparations of G-CSF |
| US5595722A (en) * | 1993-01-28 | 1997-01-21 | Neorx Corporation | Method for identifying an agent which increases TGF-beta levels |
| US6663881B2 (en) * | 1993-01-28 | 2003-12-16 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
| US6491938B2 (en) | 1993-05-13 | 2002-12-10 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
| US5981568A (en) | 1993-01-28 | 1999-11-09 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
| US5354934A (en) † | 1993-02-04 | 1994-10-11 | Amgen Inc. | Pulmonary administration of erythropoietin |
| ATE406909T1 (en) * | 1993-05-13 | 2008-09-15 | Poniard Pharmaceuticals Inc | PREVENTION AND TREATMENT OF PATHOLOGIES ASSOCIATED WITH ABNORMAL PROLIFERATION OF SMOOTH MUSCLE CELLS |
| WO1996040098A2 (en) | 1995-06-07 | 1996-12-19 | Neorx Corporation | Prevention and treatment of cardiovascular pathologies with tamoxifen analogues |
| US6632456B1 (en) | 1993-06-24 | 2003-10-14 | Astrazeneca Ab | Compositions for inhalation |
| TW402506B (en) | 1993-06-24 | 2000-08-21 | Astra Ab | Therapeutic preparation for inhalation |
| US5830853A (en) | 1994-06-23 | 1998-11-03 | Astra Aktiebolag | Systemic administration of a therapeutic preparation |
| US20010003739A1 (en) * | 1993-06-24 | 2001-06-14 | Astrazeneca Ab | Systemic administration of a therapeutic preparation |
| IS1796B (en) * | 1993-06-24 | 2001-12-31 | Ab Astra | Inhaled polypeptide formulation composition which also contains an enhancer compound |
| US6794357B1 (en) | 1993-06-24 | 2004-09-21 | Astrazeneca Ab | Compositions for inhalation |
| US5747445A (en) * | 1993-06-24 | 1998-05-05 | Astra Aktiebolag | Therapeutic preparation for inhalation |
| US5457044A (en) * | 1993-10-29 | 1995-10-10 | Genentech, Inc. | Method for collection of aerosolized proteins by inert filtration |
| MX9603936A (en) | 1994-03-07 | 1997-05-31 | Inhale Therapeutic Syst | Methods and compositions for pulmonary delivery of insulin. |
| US6051256A (en) | 1994-03-07 | 2000-04-18 | Inhale Therapeutic Systems | Dispersible macromolecule compositions and methods for their preparation and use |
| AU696387B2 (en) | 1994-05-18 | 1998-09-10 | Inhale Therapeutic Systems, Inc. | Methods and compositions for the dry powder formulation of interferons |
| US6165976A (en) | 1994-06-23 | 2000-12-26 | Astra Aktiebolag | Therapeutic preparation for inhalation |
| US5580856A (en) * | 1994-07-15 | 1996-12-03 | Prestrelski; Steven J. | Formulation of a reconstituted protein, and method and kit for the production thereof |
| US6290991B1 (en) * | 1994-12-02 | 2001-09-18 | Quandrant Holdings Cambridge Limited | Solid dose delivery vehicle and methods of making same |
| CN1088580C (en) | 1994-12-22 | 2002-08-07 | 阿斯特拉公司 | Aerosol drug formulations |
| US6524557B1 (en) | 1994-12-22 | 2003-02-25 | Astrazeneca Ab | Aerosol formulations of peptides and proteins |
| SE9404468D0 (en) * | 1994-12-22 | 1994-12-22 | Astra Ab | Powder formulations |
| EP0806945B1 (en) * | 1994-12-22 | 2003-04-23 | AstraZeneca AB | Therapeutic preparation for inhalation containing parathyro d hormone, pth |
| US5556771A (en) * | 1995-02-10 | 1996-09-17 | Gen-Probe Incorporated | Stabilized compositions of reverse transcriptase and RNA polymerase for nucleic acid amplification |
| WO1996032096A1 (en) * | 1995-04-14 | 1996-10-17 | Inhale Therapeutic Systems | Powdered pharmaceutical formulations having improved dispersibility |
| US6165463A (en) * | 1997-10-16 | 2000-12-26 | Inhale Therapeutic Systems, Inc. | Dispersible antibody compositions and methods for their preparation and use |
| US6019968A (en) * | 1995-04-14 | 2000-02-01 | Inhale Therapeutic Systems, Inc. | Dispersible antibody compositions and methods for their preparation and use |
| US5780014A (en) * | 1995-04-14 | 1998-07-14 | Inhale Therapeutic Systems | Method and apparatus for pulmonary administration of dry powder alpha 1-antitrypsin |
| US6428771B1 (en) * | 1995-05-15 | 2002-08-06 | Pharmaceutical Discovery Corporation | Method for drug delivery to the pulmonary system |
| US5875776A (en) * | 1996-04-09 | 1999-03-02 | Vivorx Pharmaceuticals, Inc. | Dry powder inhaler |
| US5876992A (en) | 1996-07-03 | 1999-03-02 | Molecular Biology Resources, Inc. | Method and formulation for stabilization of enzymes |
| US20030203036A1 (en) | 2000-03-17 | 2003-10-30 | Gordon Marc S. | Systems and processes for spray drying hydrophobic drugs with hydrophilic excipients |
| GB9703673D0 (en) * | 1997-02-21 | 1997-04-09 | Bradford Particle Design Ltd | Method and apparatus for the formation of particles |
| US20060165606A1 (en) | 1997-09-29 | 2006-07-27 | Nektar Therapeutics | Pulmonary delivery particles comprising water insoluble or crystalline active agents |
| US6565885B1 (en) | 1997-09-29 | 2003-05-20 | Inhale Therapeutic Systems, Inc. | Methods of spray drying pharmaceutical compositions |
| IE970801A1 (en) * | 1997-11-11 | 1999-05-19 | Helsinn Chemicals Ireland Ltd | An apparatus for producing a pharmaceutical product |
| US6284282B1 (en) | 1998-04-29 | 2001-09-04 | Genentech, Inc. | Method of spray freeze drying proteins for pharmaceutical administration |
| US6451349B1 (en) * | 1998-08-19 | 2002-09-17 | Quadrant Healthcare (Uk) Limited | Spray-drying process for the preparation of microparticles |
| US6907679B2 (en) * | 1998-11-12 | 2005-06-21 | Qlt Usa, Inc. | Method for lyophilizing an active agent |
| US9006175B2 (en) | 1999-06-29 | 2015-04-14 | Mannkind Corporation | Potentiation of glucose elimination |
| AU779986B2 (en) * | 1999-06-29 | 2005-02-24 | Mannkind Corporation | Purification and stabilization of peptide and protein pharmaceutical agents |
| US7029700B2 (en) * | 2000-01-14 | 2006-04-18 | Brown University Research Foundation | Micronized freeze-dried particles |
| AU2001231000A1 (en) | 2000-01-19 | 2001-07-31 | Pharmaceutical Discovery Corporation | Dry powder formulations of antihistamine for nasal administration |
| AU6124601A (en) | 2000-05-10 | 2001-11-20 | Alliance Pharmaceutical Corporation | Phospholipid-based powders for drug delivery |
| US7871598B1 (en) | 2000-05-10 | 2011-01-18 | Novartis Ag | Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use |
| US8404217B2 (en) | 2000-05-10 | 2013-03-26 | Novartis Ag | Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use |
| US7575761B2 (en) | 2000-06-30 | 2009-08-18 | Novartis Pharma Ag | Spray drying process control of drying kinetics |
| GB0027357D0 (en) | 2000-11-09 | 2000-12-27 | Bradford Particle Design Plc | Particle formation methods and their products |
| DE60217367T2 (en) * | 2001-09-19 | 2007-10-18 | Elan Pharma International Ltd. | NANOPARTICLE COMPOSITIONS CONTAINING INSULIN |
| AU2002366267B2 (en) * | 2001-11-19 | 2007-05-10 | Becton, Dickinson And Company | Pharmaceutical compositions in particulate form |
| JP2005514393A (en) | 2001-12-19 | 2005-05-19 | ネクター セラピューティクス | Supplying aminoglycosides to the lung |
| ES2300568T3 (en) | 2002-03-20 | 2008-06-16 | Mannkind Corporation | INHALATION APPARATUS |
| GB0216562D0 (en) | 2002-04-25 | 2002-08-28 | Bradford Particle Design Ltd | Particulate materials |
| US9339459B2 (en) | 2003-04-24 | 2016-05-17 | Nektar Therapeutics | Particulate materials |
| US20040077540A1 (en) * | 2002-06-28 | 2004-04-22 | Nastech Pharmaceutical Company Inc. | Compositions and methods for modulating physiology of epithelial junctional adhesion molecules for enhanced mucosal delivery of therapeutic compounds |
| DE10234165B4 (en) * | 2002-07-26 | 2008-01-03 | Advanced Micro Devices, Inc., Sunnyvale | A method of filling a trench formed in a substrate with an insulating material |
| US20050181059A1 (en) * | 2003-09-30 | 2005-08-18 | Spherics, Inc. | Nanoparticulate therapeutic biologically active agents |
| US7338171B2 (en) * | 2003-10-27 | 2008-03-04 | Jen-Chuen Hsieh | Method and apparatus for visual drive control |
| JP2007517892A (en) * | 2004-01-12 | 2007-07-05 | マンカインド コーポレイション | Methods for reducing serum proinsulin levels in type 2 diabetes |
| US20080090753A1 (en) | 2004-03-12 | 2008-04-17 | Biodel, Inc. | Rapid Acting Injectable Insulin Compositions |
| MX2007001903A (en) | 2004-08-20 | 2007-08-02 | Mannkind Corp | Catalysis of diketopiperazine synthesis. |
| KR101306384B1 (en) | 2004-08-23 | 2013-09-09 | 맨카인드 코포레이션 | Diketopiperazine salts, diketomorpholine salts or diketodioxane salts for drug delivery |
| WO2006078841A1 (en) * | 2005-01-21 | 2006-07-27 | President And Fellows Of Harvard College | Systems and methods for forming fluidic droplets encapsulated in particles such as colloidal particles |
| US8074906B2 (en) * | 2005-07-07 | 2011-12-13 | Nanotherapeutics, Inc. | Process for milling and preparing powders and compositions produced thereby |
| JP5465878B2 (en) | 2005-09-14 | 2014-04-09 | マンカインド コーポレイション | Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents |
| US7713929B2 (en) | 2006-04-12 | 2010-05-11 | Biodel Inc. | Rapid acting and long acting insulin combination formulations |
| US8084420B2 (en) | 2005-09-29 | 2011-12-27 | Biodel Inc. | Rapid acting and long acting insulin combination formulations |
| US20070086952A1 (en) * | 2005-09-29 | 2007-04-19 | Biodel, Inc. | Rapid Acting and Prolonged Acting Inhalable Insulin Preparations |
| CN104383546B (en) | 2006-02-22 | 2021-03-02 | 曼金德公司 | Method for improving the pharmaceutical properties of microparticles comprising diketopiperazines and an active agent |
| WO2007121256A2 (en) | 2006-04-12 | 2007-10-25 | Biodel, Inc. | Rapid acting and long acting insulin combination formulations |
| BRPI0718145B8 (en) * | 2006-11-02 | 2021-05-25 | Omrix Biopharmaceuticals Ltd | micronization method |
| GB0622818D0 (en) * | 2006-11-15 | 2006-12-27 | Jagotec Ag | Improvements in or relating to organic compounds |
| WO2008124522A2 (en) * | 2007-04-04 | 2008-10-16 | Biodel, Inc. | Amylin formulations |
| KR100947290B1 (en) | 2007-06-13 | 2010-03-16 | 이희영 | Scaffolds Using Human Accessory Organ Containing Keratin for Human Volume Replacement or Cell Culture and Use Thereof |
| CA3123813A1 (en) | 2007-12-04 | 2009-06-11 | Biogen Chesapeake Llc | Improved glibenclamide formulations and methods for lyophilization thereof and lyophilates provided thereby |
| US8485180B2 (en) | 2008-06-13 | 2013-07-16 | Mannkind Corporation | Dry powder drug delivery system |
| CN104689432B (en) | 2008-06-13 | 2018-07-06 | 曼金德公司 | Diskus and the system for drug conveying |
| JP5479465B2 (en) | 2008-06-20 | 2014-04-23 | マンカインド コーポレイション | Interactive device and method for profiling inhalation efforts in real time |
| US8399018B2 (en) * | 2008-07-21 | 2013-03-19 | Otonomy, Inc. | Controlled release ion channel modulator compositions and methods for the treatment of otic disorders |
| TWI494123B (en) | 2008-08-11 | 2015-08-01 | Mannkind Corp | Use of ultrarapid acting insulin |
| US8314106B2 (en) | 2008-12-29 | 2012-11-20 | Mannkind Corporation | Substituted diketopiperazine analogs for use as drug delivery agents |
| US9060927B2 (en) | 2009-03-03 | 2015-06-23 | Biodel Inc. | Insulin formulations for rapid uptake |
| PL2405963T3 (en) | 2009-03-11 | 2014-04-30 | Mannkind Corp | Apparatus, system and method for measuring resistance of an inhaler |
| EP2440184B1 (en) | 2009-06-12 | 2023-04-05 | MannKind Corporation | Diketopiperazine microparticles with defined specific surface areas |
| WO2011056889A1 (en) | 2009-11-03 | 2011-05-12 | Mannkind Corporation | An apparatus and method for simulating inhalation efforts |
| RU2571331C1 (en) | 2010-06-21 | 2015-12-20 | Маннкайнд Корпорейшн | Systems and methods for dry powder drug delivery |
| MX350838B (en) | 2011-02-11 | 2017-09-18 | Grain Proc Corporation * | Salt composition. |
| DK2694402T3 (en) | 2011-04-01 | 2017-07-03 | Mannkind Corp | BLISTER PACKAGE FOR PHARMACEUTICAL CYLINDER AMPULS |
| WO2012174472A1 (en) | 2011-06-17 | 2012-12-20 | Mannkind Corporation | High capacity diketopiperazine microparticles |
| AU2012328885B2 (en) | 2011-10-24 | 2017-08-31 | Mannkind Corporation | Methods and compositions for treating pain |
| MX354988B (en) | 2011-10-25 | 2018-03-28 | Prothena Biosciences Ltd | Antibody formulations and methods. |
| AU2013289957B2 (en) | 2012-07-12 | 2017-02-23 | Mannkind Corporation | Dry powder drug delivery systems and methods |
| US10485785B2 (en) * | 2012-07-19 | 2019-11-26 | Moriroku Chemicals Company, Ltd. | Method for producing fine powder and the fine powder produced by the same |
| WO2014066856A1 (en) | 2012-10-26 | 2014-05-01 | Mannkind Corporation | Inhalable influenza vaccine compositions and methods |
| EP3587404B1 (en) | 2013-03-15 | 2022-07-13 | MannKind Corporation | Microcrystalline diketopiperazine compositions, methods for preparation and use thereof |
| BR112016000937A8 (en) | 2013-07-18 | 2021-06-22 | Mannkind Corp | dry powder pharmaceutical formulations, method for making a dry powder formulation and use of a dry powder pharmaceutical formulation |
| JP2016530930A (en) | 2013-08-05 | 2016-10-06 | マンカインド コーポレイション | Ventilation device and method |
| WO2015148905A1 (en) | 2014-03-28 | 2015-10-01 | Mannkind Corporation | Use of ultrarapid acting insulin |
| US10561806B2 (en) | 2014-10-02 | 2020-02-18 | Mannkind Corporation | Mouthpiece cover for an inhaler |
| WO2017136667A1 (en) | 2016-02-05 | 2017-08-10 | Tolmar Tharapeutics, Inc. | Vented cover plate for an array of syringes |
| USD908916S1 (en) | 2018-06-19 | 2021-01-26 | Tolmar Therapeutics, Inc. | Syringe restrictor plate |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4783484A (en) * | 1984-10-05 | 1988-11-08 | University Of Rochester | Particulate composition and use thereof as antimicrobial agent |
| IE58110B1 (en) * | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
| US4900734A (en) * | 1987-08-27 | 1990-02-13 | Maxson Wayne S | Novel pharmaceutical composition containing estradiol and progesterone for oral administration |
| US5011678A (en) * | 1989-02-01 | 1991-04-30 | California Biotechnology Inc. | Composition and method for administration of pharmaceutically active substances |
| EP0460064A4 (en) * | 1989-02-23 | 1992-04-01 | Rorer International (Holdings) Inc. | Therapeutic aerosol formulations |
| US5021554A (en) * | 1989-02-24 | 1991-06-04 | Eli Lilly And Company | Process for protein particle size reduction using a fluid-energy mill |
| JPH04503672A (en) * | 1989-02-27 | 1992-07-02 | イー・アイ・デュポン・ドゥ・ヌムール・アンド・カンパニー | Novel naphthalene sulfonamides as radiosensitizers |
| EP0465513A1 (en) * | 1989-03-27 | 1992-01-15 | Centocor, Inc. | FORMULATIONS FOR STABILIZING OF IgM ANTIBODIES |
| JPH05963A (en) * | 1990-04-13 | 1993-01-08 | Toray Ind Inc | Polypeptide composition |
| US5057321A (en) * | 1990-06-13 | 1991-10-15 | Alza Corporation | Dosage form comprising drug and maltodextrin |
-
1993
- 1993-01-20 AT AT93903517T patent/ATE146359T1/en not_active IP Right Cessation
- 1993-01-20 DE DE69306755T patent/DE69306755T2/en not_active Expired - Fee Related
- 1993-01-20 CA CA002127877A patent/CA2127877A1/en not_active Abandoned
- 1993-01-20 EP EP93903517A patent/EP0621774B1/en not_active Expired - Lifetime
- 1993-01-20 JP JP5512680A patent/JPH07503154A/en active Pending
- 1993-01-20 WO PCT/US1993/000373 patent/WO1993013752A1/en active IP Right Grant
- 1993-02-16 US US08/017,540 patent/US5354562A/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| DE69306755D1 (en) | 1997-01-30 |
| EP0621774A1 (en) | 1994-11-02 |
| EP0621774B1 (en) | 1996-12-18 |
| US5354562A (en) | 1994-10-11 |
| WO1993013752A1 (en) | 1993-07-22 |
| JPH07503154A (en) | 1995-04-06 |
| DE69306755T2 (en) | 1997-04-10 |
| ATE146359T1 (en) | 1997-01-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2127877A1 (en) | Improved process for preparing micronized polypeptide drugs | |
| US4774085A (en) | Pharmaceutical administration systems containing a mixture of immunomodulators | |
| KR100352541B1 (en) | Nona- and decapeptides and pharmaceutical compositions for the treatment of acquired immune deficiency comprising the same | |
| ES2387749T3 (en) | Aerosols comprising nanoparticulate drugs | |
| US8158110B2 (en) | Use of aerosolized cyclosporine for prevention and treatment of pulmonary disease | |
| EP0510731A1 (en) | LHRH Analog formulations | |
| PL182560B1 (en) | Aerodol form of a preparation of peptides and proteins | |
| HUT59940A (en) | Process for producing decapeptides antagonizing releasing hormone of lutheinizing hormone and pharmaceutical compositions containing them as active components | |
| JPH05963A (en) | Polypeptide composition | |
| CA2125685A1 (en) | Powders for inhalation and process for preparing them | |
| EP1283035A3 (en) | Therapeutic preparation for inhalation containing parathyroid hormone | |
| SA95160463B1 (en) | powders for inhalation | |
| EP1372610A2 (en) | Powder inhaler formulations | |
| US20060280691A1 (en) | Spray freeze dried liposomal ciprofloxacin powder aerosol drug delivery | |
| KR102316762B1 (en) | Dry-powder peptide medicament | |
| WO1992000107A1 (en) | Aerosol drug formulations | |
| Korner | Effect of cycloheximide on protein biosynthesis in rat liver | |
| IE914498A1 (en) | Treatment of cystic fibrosis and pharmaceutical compositions¹for use therein | |
| US6187765B1 (en) | Mometasone furoate suspensions for nebulization | |
| WO1991004019A1 (en) | Therapeutic peptides and proteins | |
| HUT64776A (en) | Methods for producing cyclopeptides promoting absorption of peptides and albumins through mucous membrane as well as pharmaceutical preparations containing said compounds as auxiliary agents | |
| KR100609672B1 (en) | Liquid crystal forms of cyclosporin | |
| Sone et al. | A dried preparation of liposomes containing muramyl tripeptide phosphatidylethanolamine as a potent activator of human blood monocytes to the antitumor state | |
| CA2695127A1 (en) | Methods of treating blood cell depletion | |
| JP2003034652A (en) | Powder preparation and manufacturing method of the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |